{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:57:23Z","timestamp":1785855443637,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","award":["25000.088390\/2022-86"],"award-info":[{"award-number":["25000.088390\/2022-86"]}],"id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eplepsyres.2025.107559","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:05:04Z","timestamp":1744974304000},"page":"107559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cannabis derivatives and their synthetic analogs for treatment-resistant epilepsy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"214","author":[{"given":"Ana Luiza Cabrera","family":"Martimbianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Borges","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina de Oliveira","family":"Cruz Latorraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Porto","family":"de Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-8471","authenticated-orcid":false,"given":"Rafael Leite","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica","family":"Colpani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107559_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40001-024-01788-6","article-title":"The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet syndrome: a narrative review of clinical trials","volume":"29","author":"Aderinto","year":"2024","journal-title":"Eur. J. Med Res"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107559_bib2","first-page":"1","article-title":"Epilepsy and cannabidiol: a guide to treatment","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epileptic Disord."},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107559_bib3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1089\/can.2020.0075","article-title":"A phase 2 randomized controlled trial of the efficacy and safety of cannabidivarin as add-on therapy in participants with inadequately controlled focal seizures","volume":"6","author":"Brodie","year":"2021","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107559_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","article-title":"Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory","volume":"39","author":"Cramer","year":"1998","journal-title":"Epilepsia"},{"issue":"16_ement","key":"10.1016\/j.eplepsyres.2025.107559_bib5","article-title":"Cannabidiol (CBD) reduces convulsive seizure frequency in Dravet syndrome: results of a multi-center, randomized, controlled trial (GWPCARE1) (CT.001)","volume":"88","author":"Cross","year":"2017","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.eplepsyres.2025.107559_bib6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.eplepsyres.2025.107559_bib7","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.eplepsyres.2025.107559_bib8","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.eplepsyres.2025.107559_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.54.10.873","article-title":"The Chalfont seizure severity scale","volume":"54","author":"Duncan","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1143783","article-title":"The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial","volume":"14","author":"Ebadi","year":"2023","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107559_bib11","first-page":"47","article-title":"Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations","volume":"38","author":"Espinosa-Jovel","year":"2023","journal-title":"Neurologia"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib12","unstructured":"European Medicines Agency (EMA), 2023. Epidiolex (cannabidiol). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex."},{"issue":"4","key":"10.1016\/j.eplepsyres.2025.107559_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9126","article-title":"Adverse Events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis","volume":"6","author":"Fazlollahi","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib14","unstructured":"Food and Drug Administration (FDA), 2018. FDA NEWS RELEASE. FDA approves first drug comprised of an active ingredient derived from Marijuana to treat rare, severe forms of epilepsy. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms."},{"issue":"16","key":"10.1016\/j.eplepsyres.2025.107559_bib15","article-title":"Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)","volume":"88","author":"French","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.966721","article-title":"Psychiatric symptoms and comorbidities in patients with drug-resistant epilepsy in presurgical assessment-a prospective explorative single center study","volume":"13","author":"Friedrich","year":"2022","journal-title":"Front. Psychiatry"},{"issue":". 15","key":"10.1016\/j.eplepsyres.2025.107559_bib17","article-title":"Effect of pharmaceutical formulation of purified cannabidiol (CBD) on seizure frequency and severity is independent of drug-drug interactions with other anti-epileptic drugs (AEDs) (P4.271)","volume":"90","author":"Gaston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2019.03.035","article-title":"Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy","volume":"95","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib19","doi-asserted-by":"crossref","unstructured":"GBD 2016 Epilepsy Collaborators, 2019. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18(4):357-375. doi: 10.1016\/S1474-4422(18)30454-X. Epub 2019 Feb 14. Erratum in: Lancet Neurol. 2019 May;18(5):e4.","DOI":"10.1016\/S1474-4422(19)30120-6"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107559_bib20","article-title":"Cannabinoids for epilepsy","author":"Gloss","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib23","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., , 2023. Cochrane handbook for systematic reviews of interventions version 6.3. www.training.cochrane.org\/handbook.."},{"issue":"4","key":"10.1016\/j.eplepsyres.2025.107559_bib24","doi-asserted-by":"crossref","DOI":"10.3171\/2015.4.JNS14438","article-title":"Hemispheric surgery for refractory epilepsy: a systematic review and meta-analysis with emphasis on seizure predictors and outcomes","volume":"124","author":"Hu","year":"2016","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib25","first-page":"S293","article-title":"Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in lennox-gastaut syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4)","volume":"82","author":"Joshi","year":"2017","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107559_bib26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107559_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","article-title":"Adjunctive cannabidiol in patients with dravet syndrome: a systematic review and meta-analysis of efficacy and safety","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231207755","article-title":"Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib29","unstructured":"Madras, M.K., 2015. Update of cannabis and its medical use. World Health Organization. 37th ECDD. https:\/\/www.ncsbn.org\/public-files\/WHO_Cannabis_and_its_medical_use.pdf."},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107559_bib30","article-title":"Ketogenic diets for drug-resistant epilepsy","volume":"6","author":"Martin-McGill","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"S2","key":"10.1016\/j.eplepsyres.2025.107559_bib31","first-page":"5","article-title":"Time to onset of efficacy of cannabidiol (CBD) during titration in patients With Lennox- Gastaut syndrome or Dravet syndrome enrolled in three randomised controlled trials","volume":"60","author":"Mazurkiewicz-Beldzinska","year":"2019","journal-title":"Epilepsia"},{"issue":". 5","key":"10.1016\/j.eplepsyres.2025.107559_bib32","first-page":"S5","article-title":"Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in lennox-gastaut syndrome (lgs): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4)","volume":"58","author":"Mazurkiewicz-Beldzinska","year":"2017","journal-title":"Epilepsia"},{"issue":"24","key":"10.1016\/j.eplepsyres.2025.107559_bib33","article-title":"Transdermal cannabidiol (CBD) gel for the treatment of focal epilepsy in adults","volume":"90","author":"Messenheimer","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.eplepsyres.2025.107559_bib34","first-page":"e530","article-title":"Cannabidiol (10 and 20 mg\/kg\/d) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome: results of a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial (GWPCARE2)","volume":"93","author":"Miller","year":"2019","journal-title":"Neurology"},{"issue":"S2","key":"10.1016\/j.eplepsyres.2025.107559_bib35","first-page":"5","article-title":"Cannabidiol (CBD; 10 And 20 MG\/KG\/Day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome: results of a dose- ranging, multi- center, randomised, double- blind, placebo- controlled trial (GWPCARE2)","volume":"60","author":"Miller","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib36","doi-asserted-by":"crossref","unstructured":"Miller, I., Scheffer, I.E., Gunning, B., GWPCARE2 Study Group, 2020. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 77(5):613-621. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0073 Erratum in: JAMA Neurol. 2020. 77(5):655. PMID: 32119035; PMCID: PMC7052786.","DOI":"10.1001\/jamaneurol.2020.0073"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib37","unstructured":"National Institute for Health Care and Excellence (NICE), 2019. Cannabidiol with clobazam for treating seizures associated with Lennox\u2013Gastaut syndrome. Technology appraisal guidance. Reference number: TA615. https:\/\/www.nice.org.uk\/guidance\/ta615\/chapter\/1-Recommendations."},{"issue":"7","key":"10.1016\/j.eplepsyres.2025.107559_bib38","article-title":"Adjunctive transdermal cannabidiol for adults with focal epilepsy: a randomized clinical trial","volume":"5","author":"O'Brien","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib40","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.eplepsyres.2025.107559_bib41","first-page":"e98","article-title":"Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results ofa dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3)","volume":"89","author":"Patel","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib42","article-title":"Cannabidiol (CBD) significantly reduces convulsive seizure frequency in Dravet syndrome: results of a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial","author":"Perry","year":"2019","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107559_bib43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1590\/0004-282x-anp-2020-0202","article-title":"High prevalence of psychiatric comorbidities in children and adolescents at a tertiary epilepsy center","volume":"79","author":"Serra-Pinheiro","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib44","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00415-023-12165-4","article-title":"Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011-2021","volume":"271","author":"Shankar","year":"2024","journal-title":"J. Neurol."},{"issue":"01","key":"10.1016\/j.eplepsyres.2025.107559_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0040-1712777","article-title":"Management of refractory epilepsy","volume":"06","author":"Singh","year":"2020","journal-title":"Int J. Epilepsy"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107559_bib46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/epi.17496","article-title":"Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: four-year results from the expanded access program","volume":"64","author":"Szaflarski","year":"2023","journal-title":"Epilepsia"},{"issue":"10125","key":"10.1016\/j.eplepsyres.2025.107559_bib47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2025.107559_bib48","first-page":"810","article-title":"Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in lennox gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4)","volume":"14","author":"Thiele","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"21","key":"10.1016\/j.eplepsyres.2025.107559_bib49","article-title":"Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3)","volume":"82","author":"Wirrell","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib50","unstructured":"World health Organization (WHO), 2024. Epilepsy. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy\/?gad_source=\u20091&gclid=Cj0KCQjwlZixBhCoARIsAIC745B-ejFm5sHmjRs1EEq6noYofaI8grMmulIpWWNMxLY_81NuUn52IgUaAtEkEALw_wcB."},{"key":"10.1016\/j.eplepsyres.2025.107559_bib51","article-title":"Cannabidiol (CBD) in dravet syndrome: a randomised, dose-ranging pharmacokinetics and safety trial (GWPCARE1)","volume":"58","author":"Wright","year":"2017","journal-title":"Epilepsia"},{"issue":". 5","key":"10.1016\/j.eplepsyres.2025.107559_bib52","article-title":"Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3)","volume":"58","author":"Zuberi","year":"2017","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:45:33Z","timestamp":1778546733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121125000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":52,"alternative-id":["S0920121125000609"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107559","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabis derivatives and their synthetic analogs for treatment-resistant epilepsy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107559"}}